Literature DB >> 25869386

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.

Yanping Xiao1, Gordon J Freeman2.   

Abstract

HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25869386      PMCID： PMC4433776          DOI： 10.1158/1078-0432.CCR-14-2658

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3).

Authors:  D L Mager; D G Hunter; M Schertzer; J D Freeman
Journal:  Genomics       Date:  1999-08-01       Impact factor: 5.736

2.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

3.  Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.

Authors:  Martin F Flajnik; Tereza Tlapakova; Michael F Criscitiello; Vladimir Krylov; Yuko Ohta
Journal:  Immunogenetics       Date:  2012-04-11       Impact factor: 2.846

4.  Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.

Authors:  Murali Janakiram; Jordan M Chinai; Susan Fineberg; Andras Fiser; Cristina Montagna; Ramadevi Medavarapu; Ekaterina Castano; Hyungjun Jeon; Kim C Ohaegbulam; Ruihua Zhao; Aimin Zhao; Steven C Almo; Joseph A Sparano; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2014-12-30       Impact factor: 12.531

5.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

6.  Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis.

Authors:  Nader Rahimi; Kobra Rezazadeh; John E Mahoney; Edward Hartsough; Rosana D Meyer
Journal:  Mol Biol Cell       Date:  2012-03-14       Impact factor: 4.138

7.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

8.  B7-H5 costimulates human T cells via CD28H.

Authors:  Yuwen Zhu; Sheng Yao; Bettina P Iliopoulou; Xue Han; Mathew M Augustine; Haiying Xu; Ryan T Phennicie; Sarah J Flies; Megan Broadwater; William Ruff; Janis M Taube; Linghua Zheng; Liqun Luo; Gefeng Zhu; Jianzhu Chen; Lieping Chen
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919
  8 in total
  24 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 2.  Immunotherapy in human colorectal cancer: Challenges and prospective.

Authors:  Xuan Sun; Jian Suo; Jun Yan
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.

Authors:  Han Yan; Wanglong Qiu; Anne K Koehne de Gonzalez; Ji-Shu Wei; Min Tu; Chun-Hua Xi; Ye-Ran Yang; Yun-Peng Peng; Wei-Yann Tsai; Helen E Remotti; Yi Miao; Gloria H Su
Journal:  Cancer Lett       Date:  2018-11-14       Impact factor: 8.679

Review 4.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.

Authors:  Guoying Zhou; Patrick P C Boor; Marco J Bruno; Dave Sprengers; Jaap Kwekkeboom
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 9.075

Review 6.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

8.  HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer.

Authors:  Guocai Xu; Yuanyuan Shi; Xiaoting Ling; Dongyan Wang; Yunyun Liu; Huaiwu Lu; Yongpai Peng; Bingzhong Zhang
Journal:  Cancer Cell Int       Date:  2021-05-07       Impact factor: 5.722

9.  HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.

Authors:  Pratistha Koirala; Michael E Roth; Jonathan Gill; Jordan M Chinai; Michelle R Ewart; Sajida Piperdi; David S Geller; Bang H Hoang; Yekaterina V Fatakhova; Maya Ghorpade; Xingxing Zang; Richard Gorlick
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

10.  KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.

Authors:  Abdulla Berjis; Julie C Konge; Kathleen M Mahoney; Alyssa N Klee; Rupal S Bhatt; Samuel S Freeman; Chun-Hau Chen; Opeyemi A Jegede; Paul J Catalano; Jean-Christophe Pignon; Maura Sticco-Ivins; Baogong Zhu; Ping Hua; Jo Soden; Jie Zhu; David F McDermott; Antonio R Arulanandam; Sabina Signoretti; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2020-11-23       Impact factor: 12.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.